Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 33.62% is 77% above its 5-year average of 19.00%, near the high end of its 5-year range (12.78%–33.62%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.24% above its 12-month average of 27.28%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 33.62%.
DEBT TO ASSETS RATIO
33.62%
DEBT TO ASSETS RATIO AVG TTM
27.28%
DEBT TO ASSETS RATIO AVG 3Y
21.47%
DEBT TO ASSETS RATIO AVG 5Y
19.00%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+23.24%
CURRENT VS 3Y AVG
+56.59%
CURRENT VS 5Y AVG
+77.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 660 covered companies
CURRENT VS SECTOR MEDIAN
+33524.24%
vs the sector median at left
Definitive Healthcare Corp.
Market Cap
$105.28M
Debt to Assets Ratio
33.62%
TTM Avg
27.28%
3Y Avg
21.47%
5Y Avg
19.00%
Market Cap
$108.02M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$102.05M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.48M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.87M
Debt to Assets Ratio
0.14%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.98M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.07M
Debt to Assets Ratio
0.65%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definitive Healthcare Corp. (DH) | $105.28M | 33.62% | 27.28% | 21.47% | 19.00% |
| The Joint Corp. (JYNT)vs › | $102.45M | 0.04% | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.02M | 0.03% | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.05M | 0.01% | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $108.48M | 0.07% | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.87M | 0.14% | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $108.97M | 0.00% | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $108.98M | 0.01% | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.07M | 0.65% | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $109.75M | 0.70% | N/A | N/A | N/A |
Debt/Assets
33.6%
Debt/Equity
1.15
Current Ratio
1.86
Interest Coverage
-1.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 33.62% |
| 2026-03-31 | 33.00% |
| 2025-12-31 | 23.48% |
| 2025-09-30 | 23.22% |
| 2025-06-30 | 23.11% |
| 2025-03-31 | 22.33% |
| 2024-12-31 | 23.23% |
| 2024-09-30 | 21.77% |
| 2024-06-30 | 18.29% |
| 2024-03-31 | 14.59% |
| 2023-12-31 | 14.67% |
| 2023-09-30 | 14.93% |
| 2023-06-30 | 12.92% |
| 2023-03-31 | 12.95% |
| 2022-12-31 | 13.00% |
| 2022-09-30 | 13.12% |
| 2022-06-30 | 13.21% |
| 2022-03-31 | 13.51% |
| 2021-12-31 | 12.78% |
| 2021-09-30 | 14.56% |
| 2021-09-17 | 26.63% |
| 2021-03-31 | 26.54% |
| 2020-12-31 | 26.46% |
